Azurity is lined up to copy 1 of the blockbuster drugs on this tracker, which earned $2.1B combined in 2025.
| Drug | Brand owner | Copy | US LOE | Azurity's stage | 2025 brand sales |
|---|---|---|---|---|---|
| Cabometyx | Exelixis | Generic | 2031 | Tentative approval (different strengths); sued | $2.1B |
Each drug page lists sources for these entries. Brand sales show the size of the market, not Azurity's share of it.